Nexentis Technologies Inc. (NASDAQ: NXTS), a drug discovery company that is also investing in solar energy assets based on the RTB(ReadytoBuild) business model, is proud to announce the launch of its new corporate website at www.nexentistech.com. This digital milestone follows the company's recent rebranding from N2OFF, Inc., and underscores its commitment to advancing mitochondrial biology for breakthroughs in precision oncology and inflammatory metabolic diseases.
The newly launched website serves as a comprehensive hub for stakeholders, including investors, partners, and the scientific community, to explore Nexentis' transformative platform. Key features include detailed insights into the company's proprietary MITOLINE™ discovery engine, powered by advanced algorithms and structure-guided virtual screening workflows.
Visitors can learn about the integration of MitoCareX Bio Ltd., Nexentis' wholly owned subsidiary, which targets the mitochondrial SLC25 carrier family to develop first-in-class small-molecule programs. The site also highlights the company's non-core solar energy investments under the Ready-to-Build (RTB) model, emphasizing a balanced approach to value creation.
"We are thrilled to introduce our new website as the digital face of Nexentis Technologies," said CEO David Palach. "This launch represents more than a rebranding- it's a gateway to our vision of leveraging cutting-edge AI and mitochondrial science to address unmet needs in oncology and metabolic disorders.
NXTS shares forged ahead one cent, or 1.1%, to 87 cents.
